Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061880 · ClinicalTrials.gov registry record · Phase 1
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase 1 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00061880: Completed Phase 1 study, sponsored by BioCryst Pharmaceuticals.
NCT00061880 is a Phase 1 study that has completed, run by BioCryst Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00061880, a Phase 1 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.
Interventions
- DRUG forodesine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-02 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
What the finished NCT00061880 record still lists
NCT00061880 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which forodesine hydrochloride is the first listed.
NCT00061880 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00061880 about?
NCT00061880 is a clinical study titled "BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma". RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.
What is the current status of trial NCT00061880?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-02. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00061880?
The interventions under investigation include: forodesine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00061880?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia